AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01579292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based physical activity with intervention
Description: This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
Study NCT01579292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer Only
Description: This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
Study NCT05194280 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic surgery
Description: Robotic-assisted donornephrectomy
Study NCT03455088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: fluoxetine
Description: Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
Study NCT03455088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: fluoxetine
Description: Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
Study NCT03870880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg
Description: Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
Study NCT03870880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 100 mg
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study NCT02220764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teeth abutment
Study NCT02220764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant abutments
Study NCT01499264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MySkin patch
Description: Hydrogel and polyurethane film
Study NCT01499264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Dressing
Description: Gauze and Patch
Study NCT04335890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with IKKb matured Dendritic Cells
Description: IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
Study NCT02386319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Gelatin capsules
Study NCT02386319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT04998565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Reverse pressure applied to the areola
Study NCT04998565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Acupuncture
Description: Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
Study NCT04998565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation over bil breasts
Study NCT01069198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole, Iron, Zinc and Vitamin A
Description: single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged \<5 and >=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
Study NCT01069198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01856725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic measurements for CRT device programming
Study NCT01856725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT device implant with MultiPoint Pacing
Study NCT01003249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg.
Study NCT01856725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT device implant with MultiPoint Pacing
Study NCT03028207 — intervention group
Intervention type: PROCEDURE
Intervention: Medical tests
Description: During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
Study NCT03028207 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
Study NCT01971528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic muscle stimulator
Description: Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
Study NCT01971528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength training
Description: Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
Study NCT02714218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV
Description: Followed by Nivolumab monotherapy
Study NCT02714218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg IV
Description: Followed by Nivolumab monotherapy
Study NCT02714218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg IV
Study NCT02714218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg IV
Study NCT02714218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab 6 mg/kg IV
Description: A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to \~ 480mg.
Study NCT02881853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb7195
Study NCT02881853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01275846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Guide using AHA heart failure protocols and content
Description: Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
Study NCT04409145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT30
Description: VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.
Study NCT01942577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NoSting
Description: Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
Study NCT02254317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 mg placebo
Description: Not containing GSE (Placebo)
Study NCT02254317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg GSE
Description: 300 mg GSE
Study NCT02254317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 mg GSE
Description: Containing 600 mg of GSE
Study NCT02254317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 900 mg GSE
Description: Containing 900 mg of GSE
Study NCT01381211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE-DEB
Description: Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
Study NCT01381211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90Y-RE
Description: Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
Study NCT00420420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0249
Description: MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
Study NCT00420420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
Study NCT01422200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2011-2012 seasonal flu vaccine Subcutaneous
Study NCT01422200 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2011-2012 seasonal flu vaccine Intramuscular
Study NCT00918866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
Study NCT03236467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Exercise Training
Description: Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
Study NCT02066844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celestone
Description: 2cc
Study NCT02066844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone
Description: 2cc
Study NCT02066844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 5cc
Study NCT02066844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5cc
Study NCT01707173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education
Description: Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
Study NCT01707173 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Education
Description: Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
Study NCT03483623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NATO WELP combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
Study NCT03483623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NATO FIS combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
Study NCT03483623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAVEN WELP combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
Study NCT02412696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure
Description: Auto-titrating PAP + nasal dilator strips during sleep
Study NCT02412696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Dilator Strips
Description: Nasal dilator strips
Study NCT02412696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Dilator Strips
Description: Nasal dilator strips
Study NCT02965573 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARGX-113
Study NCT02965573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01582828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial (surgical) ablation
Description: * Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure
Study NCT01582828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid
Description: Epicardial (surgical) ablation~* Pulmonary vein isolation with bipolar clamps and bipolar box lesion~* Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation
Study NCT04272255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: scopolamine HBr
Description: Nasal Gel
Study NCT04272255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: scopolamine HBr
Description: Nasal Gel
Study NCT03104192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Develop & Refine MOWI w/o Amulet
Description: The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
Study NCT04272255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Scopolamine
Description: Patch
Study NCT04183218 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection
Study NCT04183218 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Event Monitor
Description: Receive cardiac monitor
Study NCT03483623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAVEN FIS combination
Description: Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
Study NCT02440152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suzhou Sceneray® DBS System
Description: We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
Study NCT04598152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS - transcranial direct current stimulation
Description: TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
Study NCT03891524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 25 mg
Description: Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
Study NCT03891524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 50 mg
Description: Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
Study NCT03891524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 100 mg
Description: Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
Study NCT03891524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093 200 mg
Description: Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
Study NCT03891524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-70033093, orally.
Study NCT03891524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg
Description: Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
Study NCT04183218 — intervention group
Intervention type: OTHER
Intervention: Chemoradiotherapy
Description: Undergo CRT
Study NCT04183218 — intervention group
Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03649607 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Accelerated Resolution Therapy
Description: ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
Study NCT02802007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elipse Intragastric Balloon
Study NCT03104192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOWI Weight Loss Maintenance
Description: Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).